Interestingly, analysis of The Cancer Genome Atlas (TCGA) showed that high levels of SASS6 expression were consistent with poor prognosis in adrenocortical carcinoma, low-grade glioma, and kidney, liver, and lung cancer patients. This evidence concerns the gene SASS6 and adrenal cortex carcinoma.